AEQUUS PHARMACEUTICALS INCAEQUUS PHARMACEUTICALS INCAEQUUS PHARMACEUTICALS INC

AEQUUS PHARMACEUTICALS INC

No trades
See on Supercharts

AQS fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Aequus Pharmaceuticals, Inc. engages in the development and commercialization of alternatives to currently approved drugs. Its product include, Tacrolimus IR, which are used for the treatment of refractory rejection in patients receiving allogenic liver, kidney or heart transplants; and Vistitan, and are used for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. The company was founded by Fotios Plakogiannis, Charlie Perperidis, Peter Gregory Wilson, Alexander Goumeniouk, Douglas Glen Janzen and Anne Michelle Stevens on January 3, 2013 and is headquartered in Vancouver, Canada.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
AQS has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company